research use only

CY-09 NLRP3 inhibitor

Cat.No.S5774

CY-09 is a specific NLRP3 inflammasome inhibitor that directly targeted NLRP3 itself. It is tested against the five major cytochrome P450 enzymes 1A2, 2C9, 2C19, 2D6, and 3A4 with half maximal inhibitory concentration (IC50) values of 18.9, 8.18, >50, >50, and 26.0 µM, respectively.
CY-09 NLRP3 inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 423.43

Jump to

Quality Control

Batch: Purity: 99.85%
99.85

Solubility

In vitro
Batch:

DMSO : 85 mg/mL (200.74 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 423.43 Formula

C19H12F3NO3S2

Storage (From the date of receipt) 3 years -20°C powder
CAS No. 1073612-91-5 -- Storage of Stock Solutions

Synonyms N/A Smiles C1=CC(=CC(=C1)C(F)(F)F)CN2C(=O)C(=CC3=CC=C(C=C3)C(=O)O)SC2=S

Mechanism of Action

Targets/IC50/Ki
NLRP3 inflammasome
In vitro

CY-09 specifically blocks NLRP3 activation in macrophages. This compound inhibits NLRP3 oligomerization and inflammasome assembly. It directly binds to NLRP3 and inhibits its ATPase activity. The metabolic stability of this chemical was first evaluated using human and mouse liver microsomes, exhibiting favorable stability with the half-life >145 min for both human and mouse microsomes. The metabolic stability of this compound was first evaluated using human and mouse liver microsomes, exhibiting favorable stability with the half-life >145 min for both human and mouse microsomes, which exhibited low risk of drug-drug interactions.

In vivo

CY-09 inhibits NLRP3 activation in vivo and prevents neonatal lethality in a mouse model of CAPS. In pharmacokinetic studies evaluted in C57BL/6J mice administered a single i.v. or oral dose, this compound exhibits favorable pharmacokinetics, with a half-life of 2.4 h, an area under the curve of 8,232 (h·ng)/ml, and bioavailability of 72%. It reverses metabolic disorders in diabetic mice by inhibition of NLRP3-dependent inflammation. This chemical treatment has remarkable beneficial effects for metainflammation, hyperglycemia, and insulin resistance in diabetic mice.

References

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.